References of "Van Assche, G"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailActive Foxp3 (+) Regulatory T Cells Rather Than Other Foxp3 (+) T Cells Subsets CorrelateWith Clinical Response To Infliximab Therapy For IBD
Li, Z; Vermeire, S; Bullens, D et al

Poster (2012, October)

Detailed reference viewed: 2 (1 ULg)
Full Text
Peer Reviewed
See detailRestoration Of B Cells Correlates With Clinical Response To Anti-Tnf Therapy
Li, Z; Vermeire, S; Bullens, D et al

Poster (2012, October)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailSequential T2 Relaxometry as a Non-Invasive Assessment of Transmural Inflammation in a Murine Model of Chronically Relapsing Colitis
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, May)

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailRepeated cycles of DSS inducing a chronically relapsing inflammation: a novel model to study fibrosis using in vivo MRI T2 relaxometry
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, May)

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailRepeated cycles of DSS inducing a chronically relapsing inflammation: A novel model to study fibrosis using in vivo MRI T2 relaxometry
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, February)

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailTolerability of shortened infliximab infusion times in patients with inflammatory bowel disease: a single center cohort study
Breynaert, C; Ferrante, F; Fidder, H et al

in Acta Gastro-Enterologica Belgica (2011)

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailLong term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease
Drobne, D; Bossuyt, P; Breynaert, C et al

in Journal of Crohn’s and Colitis [=JCC] (2011)

Detailed reference viewed: 36 (1 ULg)
Full Text
Peer Reviewed
See detailAnti-TNF induced skin manifestations in IBD patients: characterization and search for predisposing factors
Cleynen, I; Van Moerkercke, W; Vande Casteele, N et al

in Acta Gastro-Enterologica Belgica (2011), 74

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailMucosal gene expression profiling differentiates early from late ileal Crohn's disease
Arijs, I; Van Lommel, L; De Hertogh, G et al

in Acta Gastro-Enterologica Belgica (2011)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailTolerability of shortened infliximab infusion times in patients with inflammatory bowel disease: a single center cohort study
Breynaert, C; Ferrante, F; Fidder, H et al

in Gut (2010)

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on intestinal mucosal gene expression of endothelial cell adhesion molecules in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5 Suppl I), -677

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailKinetics of C-Reactive Protein (CRP) following maintenance infliximab treatment in Crohn's disease identifies profiles of patients with better outcome
Jürgens, M.; Mahachie John, Jestinah ULg; Cleynen, I. et al

in Gastroenterology (2010), 138(5 (Suppl I)), -686

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailReanalysis of death risk in long-term follow-up in infliximab patients versus controls
Fidder, H.; Van Steen, Kristel ULg; Van Assche, G. et al

in Gut (2010), 59

Detailed reference viewed: 11 (6 ULg)
Full Text
Peer Reviewed
See detailIntestinal mucosal expression of matrix metalloproteinase and ADAM genes in patients with inflammatory bowel disease and the impact of infliximab therapy
Arijs, Ingrid; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5), 677

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailImmortal time bias and infliximab-related mortality and malignancy incidence
Fidder, H.; Van Steen, Kristel ULg; Van Assche, G. et al

in Gut (2010), 59

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailColonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatmen
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Acta Gastro-Enterologica Belgica (2009)

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Arijs, I.; Li, K.; Toedter, G. et al

in Gut (2009), 58(12), 1612-9

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti ... [more ▼]

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two cohorts of patients who received their first treatment with infliximab for refractory ulcerative colitis were studied. Response to infliximab was defined as endoscopic and histological healing. Total RNA from pre-treatment colonic mucosal biopsies was analysed with Affymetrix Human Genome U133 Plus 2.0 Arrays. Quantitative RT-PCR was used to confirm microarray data. RESULTS: For predicting response to infliximab treatment, pre-treatment colonic mucosal expression profiles were compared for responders and non-responders. Comparative analysis identified 179 differentially expressed probe sets in cohort A and 361 in cohort B with an overlap of 74 probe sets, representing 53 known genes, between both analyses. Comparative analysis of both cohorts combined, yielded 212 differentially expressed probe sets. The top five differentially expressed genes in a combined analysis of both cohorts were osteoprotegerin, stanniocalcin-1, prostaglandin-endoperoxide synthase 2, interleukin 13 receptor alpha 2 and interleukin 11. All proteins encoded by these genes are involved in the adaptive immune response. These markers separated responders from non-responders with 95% sensitivity and 85% specificity. CONCLUSION: Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-)response to infliximab. Further study of the pathways involved should allow a better understanding of the mechanisms of resistance to infliximab therapy in ulcerative colitis. ClinicalTrials.gov number, NCT00639821. [less ▲]

Detailed reference viewed: 10 (6 ULg)
Full Text
Peer Reviewed
See detailPredictive Value of C-Reactive Protein Level Changes On the Long Term Outcome of Infliximab in Crohn's Disease
Jürgens, M.; Schnitzler, F.; Van Steen, Kristel ULg et al

in Gastroenterology (2009), 136(5), 171

Detailed reference viewed: 13 (5 ULg)